Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 84, Issue 1, pp 187–194 | Cite as

Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer

  • Bo Li
  • Dalon Xie
  • Hui ZhangEmail author
Original Article
  • 37 Downloads

Abstract

Purpose

Bladder cancer (BC) ranks first in the incidence of urogenital tumors in China and second only to prostate cancer in the West. This study will clarify the roles and mechanism of lncRNA GHET1 in chemotherapeutic resistance of BC to Gemcitabine.

Methods

The expression of GHET1 was examined using real-time quantitative PCR. Cell Counting Kit-8 assay was applied to analyze cell proliferation and Gemcitabine sensitivity. Cell apoptosis was detected using Annexin V-FITC/PI double-stained flow cytometry. The expression of ABCC1 protein was examined using Western blotting.

Results

Firstly, the expression of GHET1 was up-regulated in BC, its high expression was relevant to high grade and muscle invasion of BC patients. Secondly, high expression of GHET1 was related to low Gemcitabine sensitivity of BC patients, and GHET1 was highly expressed in Gemcitabine-resistant BC cell lines. Thirdly, knockdown of GHET1 decreased the IC50 of Gemcitabine in Gemcitabine-resistant BC cell lines and advanced the Gemcitabine-induced cytotoxicity; GHET1 promoted Gemcitabine resistance in BC. Finally, knockdown of GHET1 also inhibited the expression of ABCC1 protein in Gemcitabine-resistant BC cells.

Conclusions

High expression of GHET1 was related with the low sensitivity to Gemcitabine of BC; GHET1 contributed to chemotherapeutic resistance to Gemcitabine in BC through up-regulating ABCC1 expression. Our findings are helpful to expound the molecular mechanism of chemotherapeutic resistance in BC.

Keywords

Bladder cancer Long noncoding RNA GHET1 Chemotherapeutic resistance Gemcitabine 

Notes

Acknowledgements

This work was supported by the National Nature Science Foundation of China (Grant Nos. 81872067, 30901480, 81301834).

Author contributions

ZL and DX carried out the experiments and performed the statistical analysis. HZ participated in the study design and drafted the manuscript. All authors read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflicts of interest to disclose.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30Google Scholar
  2. 2.
    Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132Google Scholar
  3. 3.
    Chen W, Zheng R, Zeng H, Zhang S (2016) The incidence and mortality of major cancers in China, 2012. Chin J Cancer 35(1):73Google Scholar
  4. 4.
    Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71(1):96–108Google Scholar
  5. 5.
    Buttigliero C, Tucci M, Vignani F, Scagliotti GV, Di Maio M (2017) Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. Cancer Treat Rev 54:1–9Google Scholar
  6. 6.
    Drayton RM, Catto JW (2012) Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Rev Anticancer Ther 12(2):271–281Google Scholar
  7. 7.
    Pan J, Li X, Wu W, Xue M, Hou H, Zhai W, Chen W (2016) Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. Cancer Lett 382(1):64–76Google Scholar
  8. 8.
    Liu Z, Xie D, Zhang H (2018) Long noncoding RNA neuroblastoma-associated transcript 1 gene inhibits malignant cellular phenotypes of bladder cancer through miR-21/SOCS6 axis. Cell Death Dis 9(10):1042Google Scholar
  9. 9.
    Luo Z, Pan J, Ding Y, Zhang YS, Zeng Y (2018) The function and clinical relevance of lncRNA UBE2CP3-001 in human gliomas. Arch Med Sci 14(6):1308–1320Google Scholar
  10. 10.
    Hu X, Hong Y, Shang C (2019) Knockdown of long non-coding RNA SNHG5 inhibits malignant cellular phenotypes of glioma via Wnt/CTNNB1 signaling pathway. J Cancer 10(5):1333–1340Google Scholar
  11. 11.
    Huang Y, Du J, Mi Y, Li T, Gong Y, Ouyang H, Hou Y (2018) Long non-coding RNAs contribute to the inhibition of proliferation and EMT by pterostilbene in human breast cancer. Front Oncol 8:629Google Scholar
  12. 12.
    Wang XM, Liu Y, Fan YX, Liu Z, Yuan QL, Jia M, Geng ZS, Gu L, Lu XB (2018) LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway. Cancer Biol Ther 19(7):590–597Google Scholar
  13. 13.
    Saeinasab M, Bahrami AR, González J, Marchese FP, Martinez D, Mowla SJ, Matin MM, Huarte M (2019) SNHG15 is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation, invasion and drug resistance in colorectal cancer by interacting with AIF. J Exp Clin Cancer Res. 38(1):172Google Scholar
  14. 14.
    An Q, Zhou L, Xu N (2018) Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143. Biomed Pharmacother 103:415–420Google Scholar
  15. 15.
    Zhang H, Guo Y, Song Y, Shang C (2017) Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma. Cancer Chemother Pharmacol 79(1):49–55Google Scholar
  16. 16.
    Guo Y, Zhang H, Xie D, Hu X, Song R, Zhu L (2018) Non-coding RNA NEAT1/miR-214-3p contribute to doxorubicin resistance of urothelial bladder cancer preliminary through the Wnt/β-catenin pathway. Cancer Manag Res 10:4371–4380Google Scholar
  17. 17.
    Yang F, Xue X, Zheng L, Bi J, Zhou Y, Zhi K, Gu Y, Fang G (2014) Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability. FEBS J 281(3):802–813Google Scholar
  18. 18.
    Han M, Wang Y, Gu Y, Ge X, Seng J, Guo G, Zhang X, Zhao Y, Dou D (2019) lncRNA GHET1 knockdown suppresses breast cancer activity in vitro and in vivo. Am J Transl Res 11(1):31–44Google Scholar
  19. 19.
    Ni W, Luo L, Zuo P, Li RP, Xu XB, Wen F, Hu D (2018) lncRNA GHET1 down-regulation suppresses the cell activities of glioma. Cancer Biomark 23(1):9–22Google Scholar
  20. 20.
    Xia Y, Yan Z, Wan Y, Wei S, Bi Y, Zhao J, Liu J, Liao DJ, Huang H (2018) Knockdown of long noncoding RNA GHET1 inhibits cell-cycle progression and invasion of gastric cancer cells. Mol Med Rep 18(3):3375–3381Google Scholar
  21. 21.
    Li LJ, Zhu JL, Bao WS, Chen DK, Huang W, Weng ZL (2014) Long noncoding RNA GHET1 promotes the development of bladder cancer. Int J Clin Exp Pathol 7(10):7196–7205Google Scholar
  22. 22.
    Zhang X, Bo P, Liu L, Zhang X, Li J (2017) Overexpression of long non-coding RNA GHET1 promotes the development of multidrug resistance in gastric cancer cells. Biomed Pharmacother 92:580–585Google Scholar
  23. 23.
    Li X, Wang H, Wang J, Chen Y, Yin X, Shi G, Li H, Hu Z, Liang X (2016) Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation. BMC Cancer 16:578Google Scholar
  24. 24.
    Liu Z, Zhang H (2017) LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma. Oncotarget 8(38):64273–64282Google Scholar
  25. 25.
    Xie D, Zhang H, Shang C (2018) Long non-coding RNA CDKN2B antisense RNA 1 gene inhibits Gemcitabine sensitivity in bladder urothelial carcinoma. J Cancer 9(12):2160–2166Google Scholar
  26. 26.
    Huo JF, Chen XB (2019) Long noncoding RNA growth arrest-specific 5 facilitates glioma cell sensitivity to cisplatin by suppressing excessive autophagy in an mTOR-dependent manner. J Cell Biochem 120(4):6127–6136Google Scholar
  27. 27.
    Wang M, Han D, Yuan Z, Hu H, Zhao Z, Yang R, Jin Y, Zou C, Chen Y, Wang G, Gao X, Wang X (2018) Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy. Cell Death Dis 9(12):1149Google Scholar
  28. 28.
    Zhang J, Zhao B, Chen X, Wang Z, Xu H, Huang B (2018) Silence of long noncoding RNA NEAT1 inhibits malignant biological behaviors and chemotherapy resistance in gastric cancer. Pathol Oncol Res 24(1):109–113Google Scholar
  29. 29.
    de Sousa Cavalcante L, Monteiro G (2014) Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol 741:8–16Google Scholar
  30. 30.
    Lorendeau D, Dury L, Nasr R, Boumendjel A, Teodori E, Gutschow M, Falson P, Di Pietro A, Baubichon-Cortay H (2017) MRP1-dependent collateral sensitivity of multidrug-resistant cancer cells: identifying selective modulators inducing cellular glutathione depletion. Curr Med Chem 24(12):1186–1213Google Scholar
  31. 31.
    Yan M, Wang J, Ren Y, Li L, He W, Zhang Y, Liu T, Li Z (2019) Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization. Cell Death Dis 10(3):204Google Scholar
  32. 32.
    Wang S, Meng Q, Xie Q, Zhang M (2017) Effect and mechanism of resveratrol on drug resistance in human bladder cancer cells. Mol Med Rep 15(3):1179–1187Google Scholar
  33. 33.
    Shang C, Ao CN, Cheong CC, Meng L (2019) Long non-coding RNA CDKN2B antisense RNA 1 gene contributes to paclitaxel resistance in endometrial carcinoma. Front Oncol 9:27Google Scholar
  34. 34.
    Shang C, Tang W, Pan C, Hu X, Hong Y (2018) Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma. Cancer Chemother Pharmacol 81(4):671–678Google Scholar
  35. 35.
    Cao W, Liu B, Ma H (2019) Long non-coding RNA GHET1 promotes viability, migration and invasion of glioma cell line U251 by down-regulation of miR-216a. Eur Rev Med Pharmacol Sci 23(4):1591–1599Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Urinary SurgeryShengjing Hospital, China Medical UniversityShenyangChina
  2. 2.Department of Anatomy, College of Basic Medical ScienceChina Medical UniversityShenyangChina

Personalised recommendations